TMC NEWS

TMCNET eNEWSLETTER SIGNUP

vTv Therapeutics to Present Two Posters at the 2017 Alzheimer's Association International Conference

[July 13, 2017]

vTv Therapeutics to Present Two Posters at the 2017 Alzheimer's Association International Conference

vTv Therapeutics Inc. (vTv) (Nasdaq: VTVT) today announced that data on
the company's phase 3 Alzheimer's candidate, azeliragon, an oral
antagonist of the Receptor for Advanced Glycation Endproducts (RAGE),
will be presented at the 2017 Alzheimer's Association International
Conference (AAIC) held in London, England, July 16 - 20, 2017.

Azeliragon, also known as TTP488, is a novel orally active
small-molecule antagonist of RAGE. A broad range of human pathologic and
experimental biologic investigation suggests that RAGE activation
contributes to the pathogenesis of Alzheimer's disease. Sustained
Amyloid-ß interactions with RAGE at the blood-brain barrier (BBB) and in
neuronal and microglial cells, play potentially major roles in amyloid
plaque formation, neuroinflammation and chronic neural dysfunction - all
hallmarks of Alzheimer's disease.

About vTv Therapeutics

vTv Therapeutics Inc. is a clinical-stage biopharmaceutical company
engaged in the discovery and development of orally administered small
molecule drug candidates to fill significant unmet medical needs. vTv
has a pipeline of clinical drug candidates led by programs for the
treatment of Alzheimer's disease and Type 2 diabetes as well as
treatment of inflammatory disorders and the prevention of muscle
weakness.

Forward-Looking Statements

This release contains forward-looking statements, which involve risks
and uncertainties. These forward-looking statements can be identified by
the use of forward-looking terminology, including the terms
"anticipate," "believe," "could," "estimate," "expect," "intend," "may,"
"plan," "potential," "predict," "project," "should," "target," "will,"
"would" and, in each case, their negative or other various or comparable
terminology. All statements other than statements of historical facts
contained in this release, including statements regarding the timing of
our clinical trials, our strategy, future operations, future financial
position, future revenue, projected costs, prospects, plans, objectives
of management and expected market growth are forward-looking statements.
These statements involve known and unknown risks, uncertainties and
other important factors that may cause our actual results, performance
or achievements to be materially different from any future results,
performance or achievements expressed or implied by the forward-looking
statements. Important factors that could cause our results to vary from
expectations include those described under the heading "Risk Factors" in
our Annual Report on Form 10-K and our other filings with the SEC (News - Alert). These
forward-looking statements reflect our views with respect to future
events as of the date of this release and are based on assumptions and
subject to risks and uncertainties. Given these uncertainties, you
should not place undue reliance on these forward-looking statements.
These forward-looking statements represent our estimates and assumptions
only as of the date of this release and, except as required by law, we
undertake no obligation to update or review publicly any forward-looking
statements, whether as a result of new information, future events or
otherwise after the date of this release. We anticipate that subsequent
events and developments will cause our views to change. Our
forward-looking statements do not reflect the potential impact of any
future acquisitions, merger, dispositions, joint ventures or investments
we may undertake. We qualify all of our forward-looking statements by
these cautionary statements.